Loading...
Market
What will be Ozempic's market status for Alzheimer's by 2026?
2
Resolution / Starting Odds
FDA approved and in market • 25%
Pending approval • 25%
Rejected by FDA • 25%
Withdrawn by manufacturer • 25%
FDA approval status, market reports, and pharmaceutical company announcements
Story
Ozempic Shows Promise in Reducing Advanced Alzheimer's Risk, Potential 70% Reduction in Dementia by 2025
Dec 26, 2024, 08:53 AM
Recent studies are exploring the potential of Ozempic, a weight-loss medication, to aid in the fight against advanced Alzheimer's disease. Scientists are investigating its anti-inflammatory properties, which may contribute to a significant reduction in the risk of developing dementia. Early findings indicate that patients receiving the medication could see up to a 70% reduced risk of dementia. However, further research is needed, with more comprehensive results expected in 2025.
View original story
Similar markets
More than 20% • 25%
5% to 10% • 25%
Less than 5% • 25%
10% to 20% • 25%
Somewhat positive • 25%
Neutral • 25%
Negative • 25%
Highly positive • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
No action taken • 25%
Product recall • 25%
Safety label update • 25%
Other regulatory actions • 25%
By health organizations • 25%
By Novo Nordisk • 25%
By both • 25%
No campaigns • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%